JP2018534245A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534245A5
JP2018534245A5 JP2018513462A JP2018513462A JP2018534245A5 JP 2018534245 A5 JP2018534245 A5 JP 2018534245A5 JP 2018513462 A JP2018513462 A JP 2018513462A JP 2018513462 A JP2018513462 A JP 2018513462A JP 2018534245 A5 JP2018534245 A5 JP 2018534245A5
Authority
JP
Japan
Prior art keywords
domain
family
igsf
modified
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018513462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534245A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/051786 external-priority patent/WO2017048878A1/en
Publication of JP2018534245A publication Critical patent/JP2018534245A/ja
Publication of JP2018534245A5 publication Critical patent/JP2018534245A5/ja
Pending legal-status Critical Current

Links

JP2018513462A 2015-09-14 2016-09-14 調整可能なバリアント免疫グロブリンスーパーファミリードメインおよび改変細胞療法 Pending JP2018534245A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562218531P 2015-09-14 2015-09-14
US62/218,531 2015-09-14
US201662323595P 2016-04-15 2016-04-15
US201662323608P 2016-04-15 2016-04-15
US62/323,595 2016-04-15
US62/323,608 2016-04-15
US201662367819P 2016-07-28 2016-07-28
US201662367822P 2016-07-28 2016-07-28
US62/367,822 2016-07-28
US62/367,819 2016-07-28
PCT/US2016/051786 WO2017048878A1 (en) 2015-09-14 2016-09-14 Tunable variant immunoglobulin superfamily domains and engineered cell therapy

Publications (2)

Publication Number Publication Date
JP2018534245A JP2018534245A (ja) 2018-11-22
JP2018534245A5 true JP2018534245A5 (cg-RX-API-DMAC7.html) 2019-10-24

Family

ID=57068203

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513462A Pending JP2018534245A (ja) 2015-09-14 2016-09-14 調整可能なバリアント免疫グロブリンスーパーファミリードメインおよび改変細胞療法

Country Status (12)

Country Link
US (1) US20180256644A1 (cg-RX-API-DMAC7.html)
EP (1) EP3350206A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018534245A (cg-RX-API-DMAC7.html)
KR (1) KR20180054713A (cg-RX-API-DMAC7.html)
CN (1) CN108513576A (cg-RX-API-DMAC7.html)
AU (1) AU2016323069A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018004965A2 (cg-RX-API-DMAC7.html)
CA (1) CA2997217A1 (cg-RX-API-DMAC7.html)
EA (1) EA201890729A1 (cg-RX-API-DMAC7.html)
IL (1) IL258102A (cg-RX-API-DMAC7.html)
MX (1) MX2018003144A (cg-RX-API-DMAC7.html)
WO (1) WO2017048878A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd8에의 항원 결합 구조체들
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
MX2018001566A (es) 2015-08-07 2019-04-25 Imaginab Inc Construcciones de union a antigeno para moleculas diana.
MX2018005517A (es) 2015-11-02 2018-11-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
KR20190006495A (ko) 2016-04-15 2019-01-18 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
KR20230051602A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
EP3529361B1 (en) * 2016-10-20 2021-03-24 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
EP3596115A1 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
WO2018170026A2 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
EP3628070B1 (en) 2017-04-28 2021-09-08 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides for use in increasing central memory t cells
TWI870011B (zh) 2017-08-25 2025-01-11 美商戊瑞治療有限公司 B7-h4抗體及其使用方法
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
SG11202003078VA (en) * 2017-10-18 2020-05-28 Alpine Immune Sciences Inc Variant icos ligand immunomodulatory proteins and related compositions and methods
BR112020013236A2 (pt) * 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN111741978A (zh) 2018-02-21 2020-10-02 戊瑞治疗有限公司 B7-h4抗体制剂
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
US11401339B2 (en) 2018-08-23 2022-08-02 Seagen Inc. Anti-TIGIT antibodies
EP3889263A4 (en) 2018-12-24 2022-08-17 Haidong Huang GENE CODING FOR MUTANT HUMAN 2IG-B7-H3 PROTEIN, RECOMBINANT VECTOR, HOST CELL WITH IT, PHARMACEUTICAL COMPOSITION AND USE THEREOF
KR20210117277A (ko) * 2019-01-13 2021-09-28 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 넥틴-2에 특이적인 항체
WO2020219896A1 (en) * 2019-04-26 2020-10-29 Beijing Xuanyi Pharmasciences Co., Ltd. Cd80 variant proteins and uses thereof
PH12021552979A1 (en) 2019-05-27 2023-10-09 Immatics Us Inc Viral vectors and their use in adoptive cellular therapy
AU2020345943A1 (en) 2019-09-10 2022-03-31 Obsidian Therapeutics, Inc. CA2-IL15 fusion proteins for tunable regulation
CN110859951A (zh) * 2019-09-23 2020-03-06 中国药科大学 Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用
CN113087806B (zh) * 2019-12-31 2022-09-06 华东师范大学 靶向多种肿瘤的新型car-t细胞及其制备和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773253A (en) * 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
EP1360290A2 (en) * 2000-06-23 2003-11-12 Maxygen, Inc. Co-stimulatory molecules
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
PT2856876T (pt) * 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
PT3357511T (pt) * 2011-06-30 2020-07-23 Genzyme Corp Inibidores da ativação de células t
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
RU2671465C2 (ru) * 2012-05-11 2018-10-31 Медиммьюн Лимитед Варианты ctla-4
GB201311475D0 (en) * 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
EP3283508B1 (en) * 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities

Similar Documents

Publication Publication Date Title
JP2018534245A5 (cg-RX-API-DMAC7.html)
JP2020500010A5 (cg-RX-API-DMAC7.html)
TWI809130B (zh) 嵌合跨膜蛋白及其用途
JP2018508219A5 (cg-RX-API-DMAC7.html)
JP2020511136A5 (cg-RX-API-DMAC7.html)
JP7433348B2 (ja) キメラポリペプチド及びそれらの細胞膜における局在を変更する方法
RU2018109426A (ru) Химерные антигенные рецепторы со встроенными контролируемыми функциями
IL277398B2 (en) Pd-l1 binding affimers, and uses related thereto
JP2020114264A5 (cg-RX-API-DMAC7.html)
JP2019531328A5 (cg-RX-API-DMAC7.html)
JP2017501702A5 (cg-RX-API-DMAC7.html)
Stanietsky et al. Paired NK cell receptors controlling NK cytotoxicity
US20220389075A1 (en) Engineered t cell receptors and uses thereof
RU2020135106A (ru) Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения
KR20200103703A (ko) Nkg2d 도메인을 포함하는 다중특이적 키메라 수용체 및 이의 사용 방법
NZ759969A (en) Tagged chimeric effector molecules and receptors thereof
KR20180054713A (ko) 조율가능한 변종 면역글로불린 수퍼패밀리 도메인 및 유전자 조작된 세포 치료법
JP2017519502A5 (cg-RX-API-DMAC7.html)
JP2021501587A (ja) Cd38指向性キメラ抗原受容体構築物
JP7723420B2 (ja) B細胞標的化並列CAR(pCAR)治療的薬剤
JP2019513394A5 (cg-RX-API-DMAC7.html)
JP2017518071A5 (cg-RX-API-DMAC7.html)
KR20230013257A (ko) 종양 미세환경의 역전을 위한 융합 단백질 및 이의 응용
JPWO2022178367A5 (cg-RX-API-DMAC7.html)
Shrager et al. SnapShot: APC/T cell immune checkpoints